|
キシ タカユキ
Kishi Takayuki
岸 崇之 所属 医学部 医学科（東京女子医科大学病院） 職種 講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis. |
| 掲載誌名 | 正式名：Rheumatology (Oxford, England) 略 称：Rheumatology (Oxford) ISSNコード：14620332/14620324 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 60(5),pp.2134-2145 |
| 著者・共著者 | Kishi Takayuki, Warren-Hicks William, Bayat Nastaran, Targoff Ira N, Huber Adam M, Ward Michael M, Rider Lisa G, |
| 担当区分 | 筆頭著者 |
| 発行年月 | 2021/05 |
| 概要 | OBJECTIVE:A North American registry of JDM patients was examined for frequency of and factors associated with corticosteroid discontinuation, complete clinical response and remission.METHODS:We evaluated probability of achieving final corticosteroid discontinuation, complete clinical response and remission in 307 JDM patients by Weibull time-to-event modelling; conditional probability of complete clinical response and remission using Bayesian network modelling; and significant predictors with multivariable Markov chain Monte-Carlo Weibull extension models.RESULTS:The probability of corticosteroid discontinuation was 56%, complete clinical response 38% and remission 30% by 60 months after initial treatment in 105 patients. The probability of remission was conditional on corticosteroid discontinuation and complete clinical response. Photosensitivity, contractures and a longer time to complete clinical response were predictive of the time to final corticosteroid discontinuation. Anti-MJ (NXP2) autoantibodies and a Northwest residential geoclimatic zone were predictive of shorter time to complete clinical response, while dysphonia, contractures, an increase in medications within 24 months and a longer time to corticosteroid discontinuation were associated with longer time to complete clinical response. Anti-p155/140 (TIF1) autoantibodies, an increase in medications within 12-24 months, or longer times to corticosteroid discontinuation and complete clinical response were associated with longer time to remission.CONCLUSION:JDM patients achieve favourable outcomes, including corticosteroid discontinuation, complete clinical response and remission, although timelines for these may be several years based on time-dependent analyses. These outcomes are inter-related and strong predictors of each other. Selected clinical features and myositis autoantibodies are additionally associated with these outcomes. |
| DOI | 10.1093/rheumatology/keaa371 |
| PMID | 33067611 |